Tanvex Biopharma (6541) AI Stock Analysis

Tanvex Biopharma

(TWSE:6541)

Select Model

Rating:46Neutral

Price Target:TWD 27.00▼(-4.09% Downside)

Action:initiatedcoverage

Date:11/10/26

Financial performance weighs most heavily, supported by revenue growth and balance sheet gains yet limited by losses and cash burn. Weak technical momentum adds further pressure while negative valuation metrics constrain the score.

Positive Factors

Strong Revenue GrowthThe sharp 2025 revenue increase indicates meaningful commercial expansion and improving market traction. If the growth is sustained, it can provide greater operating scale, support investment in development and market access, and strengthen the company’s ability to build a broader biologics business.

Negative Factors

Persistent Operating LossesPersistent operating and net losses show that the business has not yet reached earnings stability despite strong revenue growth. Continued losses can constrain reinvestment, weaken shareholder returns, and make future performance dependent on achieving much better operating leverage and cost control.

Tanvex Biopharma (6541) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 7.47B
Dividend Yield: ―
Average Volume (3M): 432.45K
Price to Earnings (P/E): -5.0
Beta (1Y): 0.39
Revenue Growth: 207.37%
EPS Growth: 4.17%
Country: TW
Employees: 215
Sector: General
Sector Strength: 55
Industry: Biotechnology

Tanvex Biopharma Business Overview & Revenue Model

Company Description

Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medici...

Tanvex Biopharma Financial Statement Overview

Summary

Revenue expanded sharply but gross profit turned deeply negative with large ongoing losses; balance sheet strengthened via equity raises and lower leverage, though cash burn persists.

Income Statement

28Negative

Balance Sheet

62Positive

Cash Flow

33Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	657.56M	400.97M	34.68M	61.41M	22.40M	5.41M
Gross Profit	-984.67M	-440.71M	8.29M	59.70M	-19.35M	3.55M
EBITDA	-1.02B	-1.02B	-1.04B	-1.75B	-1.30B	-1.25B
Net Income	-1.47B	-1.50B	-1.38B	-2.14B	-1.64B	-1.54B
Balance Sheet
Total Assets	7.63B	7.96B	2.74B	2.76B	3.42B	4.71B
Cash, Cash Equivalents and Short-Term Investments	592.56M	878.71M	376.96M	380.75M	786.23M	2.22B
Total Debt	2.08B	1.58B	1.65B	1.73B	1.84B	1.76B
Total Liabilities	2.67B	2.27B	1.84B	1.94B	2.03B	1.92B
Stockholders Equity	4.97B	5.69B	893.31M	821.11M	1.39B	2.79B
Cash Flow
Free Cash Flow	-1.75B	-1.68B	-1.26B	-1.51B	-1.43B	-1.42B
Operating Cash Flow	-934.97M	-1.01B	-1.15B	-1.43B	-1.33B	-1.39B
Investing Cash Flow	-784.34M	301.80M	-109.25M	-83.57M	-97.35M	-24.68M
Financing Cash Flow	1.69B	1.14B	1.26B	1.08B	-123.29M	1.60B

Tanvex Biopharma Technical Analysis

Technical Analysis SentimentNegative

Last Price28.15

Price Trends

50DMA30.87Negative

100DMA35.02Negative

200DMA39.33Negative

Market Momentum

MACD-1.01Positive

RSI41.76Neutral

STOCH65.62Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TW:6541, the sentiment is Negative. The current price of 28.15 is below the 20-day moving average (MA) of 29.32, below the 50-day MA of 30.87, and below the 200-day MA of 39.33, indicating a bearish trend. The MACD of -1.01 indicates Positive momentum. The RSI at 41.76 is Neutral, neither overbought nor oversold. The STOCH value of 65.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TW:6541.

Tanvex Biopharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6541 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6541	46Neutral	TWD 7.47B	-5.03	-26.61%	―	207.37%	4.17%

* General Sector Average

Performance Comparison

TW:6541 and its peers over the selected period
Show on chart	Ticker	Company Name	Price	Change	% Change
	TW:6541	Tanvex Biopharma	28.15	-27.35	-49.28%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 08, 2026

Tanvex Biopharma AI Stock Analysis